Conjugation of metallothionein to a murine monoclonal antibody
โ Scribed by Beverly A. Brown; Cynthia A. Drozynski; Cynthia B. Dearborn; Richard A. Hadjian; Frederick A. Liberatore; Thomas H. Tulip; Glen L. Tolman; Stephen B. Haber
- Publisher
- Elsevier Science
- Year
- 1988
- Tongue
- English
- Weight
- 554 KB
- Volume
- 172
- Category
- Article
- ISSN
- 0003-2697
No coin nor oath required. For personal study only.
โฆ Synopsis
A method of conjugation of the metal-binding protein, metallothionein, to an anticarcinoma murine monoclonal antibody, B72.3, and its F(ab'b fragment has been developed utilizing the heterobifunctional crosslinking reagent, succinimidyl4-(N-maleimidomethyl)cyclohexane l-carboxylate. This crosslinking reagent is first reacted with the free amines on the immunoglobulin. After removal of unreacted crosslinker, conjugation is affected through a sulfhydryl group on metallothionein. Under the conditions employed all immunoglobulin aggregates contained metallothionein. The degree of undesired aggregation is directly proportional to the number of metallothioneins attached to the immunoglobulin. This aggregation can be controlled by the amount ofcrosslinker and metallothionein presented to the immunoglobulin. The immunoglobulin conjugate retains full immunoreactivity and can be readily purified from the unreacted metallothionein and high molecular weight aggregates. The metallothionein-B72.3 conjugate functions as an efficient and stable chelator of radiometals. Thus metallothionein-monoclonal antibody conjugates have potential utility in cancer diagnosis and therapy. 0 1988 Academic PPS. hc.
๐ SIMILAR VOLUMES
The therapeutic effectiveness of xenogeneic monoclonal antibodies (MAbs) (xIg) or their conjugates with toxins (xIg-Tx) is undermined because of their inherent immunogenicity. This complication may be overcome by converting the antigenic xIg to tolerogenic derivatives by coupling an appropriate numb
The emergence of new therapeutic rnodalities frequently requires development of relevant laboratory assays. This is especially true for the clinical uses of newly developed reagents such as murine monoclonal antibodies. We have described immunofluorescence, immunohistochemical, and enzyme-lin ked im
We published in the journal a new four-color flow cytometric method to help diagnose, stage, monitor, and screen autologous transplant products for children with neuroblastoma (1). The ''four-color'' monoclonal antibody assay involved a ganglioside GD2/fluorescein isothiocyanate (FITC), TAPA CD81/ph
A mouse monoclonal hybridoma cell line producing IgG 1 k to human immunodeficiency virus (HIV-1) gp120 envelope protein was cultured in several systems. A small-scale flask culture was essential for characterizing the culture variables of the hybridoma. A dialysis tubing culture appeared to be an ex